Mobile

Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001918-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the persistence of anti-HAV antibodies in terms of seropositivity rate and geometric mean concentration (GMC), 21 to 25 years after the second vaccine dose.

Critère d'inclusion

  • Healthy volunteers (Vaccination against hepatitis A in healthy adults)

Liens